Dr. Thomas FladHead of Business Development
South Germany, DACH Region
We are driven by a strong customer satisfaction commitment based on highly skilled team of over 100 staff, of which approx. 60% are academics. That is underpinned by an internationally oriented highly motivated team and a highly-developed and forward thinking project management capability.
Our Business Development Team is headed by three Experts each having an academic background, excellent branche know how and long year experience in the field of anlytical excellence in biopharamceuticals. They are the experts and your reliable partner in all questions regarding your biopharmaceutical and project demands.
Thomas Flad is pharmacist by training with a PhD in biochemistry. He is a protein analytical expert and author of numerous peer-reviewed articles.
In 2004 he co-founded PANATecs GmbH as a protein analytical service company, where he served as CSO and Qualified Person for the first 4 years and then moved into Business Development for supporting Big Pharma and Biotech customers with analytical services for approval of biopharmaceuticals and vaccines until 2014.
Since 2014 he is Head of Business Development at Protagen Protein Services with responsibility for Pharma and Biotech customers in the D/A/CH region.
With more than 15 years experience in the biotech industry Thomas has profound knowledge in design and optimization of analytical CMC concepts for development and approval of biopharmaceuticals.
Marcus Mreyen holds a PhD in chemistry and has spent two years in the protein analytical field at Macquarie University and at the Australian Proteome Analysis Facility (APAF). Starting at Protagen AG in 2000 he successfully worked as a Project Manager and supported multiple customer projects in the various fields of protein characterization. He transferred and deepened his technical understanding during a time working for Shimadzu Europe, as a Product Manager for Mass Spectrometry and Life Science products. During this time he assisted customers in pharma and biotech in Europe and Russia, before returning 2013 to Protagen Protein Services as a Head for Business Development.
Since then he has supported a large variety of international companies in their Biosimilar or NBE developments from early phases of development to Phase 3, as well as for GMP release and stability testing.
Ulrike Konrad has a graduated in chemistry (Dipl.-Chem.), studied at universities in Germany and USA and obtained a MBA. She started her industry carrier at as a scientist and soon moved to a business development position at a CDMO in Heidelberg. Since 2012 she develops PPS international activities and focuses on biosimilars and protein characterization and is now responsible for PPS customers in Scandinavia, UK, Asia, Africa, Australia and Latin America in all aspects from developability through protein characterization up to release and stability testing.
Wiliam Rash began his career in the lab as a protein scientist and progressed to global leadership roles in corporate and business development. His expertise ranges from characterization and QC technologies application for pre-clinical and clinical development of recombinant protein biologics, to facilities and laboratory operational management, to Global sales and marketing. With an established career in complex biologics, Mr. Rash is adept at identifying opportunities and working with partners to tap into exciting areas in the Biopharmaceutical industry. Before joining BioAnalytix, Mr. Rash worked for Tektagen, Hospital at the University of Pennsylvania, Commonwealth Serum Laboratories, Wyeth, Charles River Laboratories, Ascent Biotechnology Recruiters, Essenix Pharmaceuticals, and Blue Stream Laboratories. Mr. Rash is a serial entrepreneur where he has played pivotal roles in four companies in the biotechnology space. Mr. Rash holds a B.S. in Microbiology from West Chester.
Protagen Protein Services (PPS) is a world leading CRO and recognized expert for analytical services in protein science. More than 20 years of market experience and the comprehensive spectrum of validated analytical methods ensure the highest quality for customers in the pharmaceutical, biotech and life science industry.
PPS supports Biosimilar developers with a broad range of analytical methods and consulting in achieving and demonstrating Biosimilarity